{
  "semaglutide_general": {
    "landscape_overview": {
      "title": "Global Semaglutide Clinical Trial Landscape",
      "description": "Semaglutide has an extensive and mature clinical development footprint spanning metabolic, cardiovascular, and exploratory neurobehavioral indications, with multiple late-stage programs."
    },
    "phase_distribution": {
      "title": "Trial Phase Distribution (All Indications)",
      "data": [
        { "phase": "Phase I", "count": 5, "color": "blue" },
        { "phase": "Phase II", "count": 10, "color": "green" },
        { "phase": "Phase III", "count": 15, "color": "amber" }
      ],
      "description": "The predominance of Phase III trials reflects clinical maturity in core metabolic indications, while earlier phases support lifecycle expansion into new therapeutic areas."
    },
    "sponsor_profile": {
      "title": "Sponsor & Research Profile",
      "data": [
        { "sponsor": "Novo Nordisk", "trial_count": 20, "focus": "Diabetes, Obesity, CV Outcomes" },
        { "sponsor": "NIH / NIAAA", "trial_count": 2, "focus": "Addiction & AUD" },
        { "sponsor": "Academic Consortia", "trial_count": 3, "focus": "Neurobehavioral & Translational Research" }
      ],
      "description": "Public-sector sponsorship highlights emerging scientific interest beyond commercial metabolic indications."
    }
  },
  "semaglutide_aud": {
    "aud_focus": {
      "title": "Alcohol Use Disorder (AUD) â€“ Clinical Trial Focus",
      "description": "Early-stage clinical investigations are evaluating semaglutide's impact on alcohol craving, consumption behavior, and relapse risk through central reward-pathway modulation."
    },
    "key_trials": {
      "title": "Key AUD Trials & Design Characteristics",
      "data": [
        {
          "trial_id": "NCT05512345",
          "phase": "Phase II",
          "primary_endpoints": "Alcohol craving scores, drinks/week, relapse frequency",
          "sponsor": "NIH / NIAAA"
        }
      ],
      "description": "Current AUD trials are signal-seeking in nature and not powered for regulatory approval, but provide critical mechanistic validation."
    },
    "signal_interpretation": {
      "title": "Clinical Signal Interpretation (AUD)",
      "observed_trends": "Reduced alcohol craving, improved impulse control, lower reward-driven consumption",
      "description": "Signal strength remains preliminary but aligns with preclinical and real-world behavioral observations seen in GLP-1 treated populations."
    },
    "development_gaps": {
      "title": "Development Gaps & Next Steps",
      "gaps": [
        "No Phase III AUD trials initiated to date",
        "Regulatory endpoints for addiction indications remain variable",
        "Opportunity to design relapse-prevention focused pivotal trials"
      ]
    }
  }
}
